Carregant...
Immunotherapy of advanced renal cell carcinoma: Current and future therapies
Previously a malignancy with few therapeutic options, metastatic renal cell carcinoma (mRCC) treatment is rapidly evolving. Although cytokine therapies (interferon-a, interleukin-2) have been used less frequently over the past decade, recent approval of an immune checkpoint inhibitor, nivolumab, has...
Guardat en:
| Publicat a: | Hum Vaccin Immunother |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215367/ https://ncbi.nlm.nih.gov/pubmed/27494417 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1212794 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|